Increased mean glucose levels in patients with polycystic ovary syndrome and hyperandrogenemia as determined by continuous glucose monitoring

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 2, 2013, Pages 165-171

  Zhu, Jie Ping ^a   Teng, Yin Cheng ^a   Zhou, Jian ^a   Lu, Wei ^a   Tao, Min Fang ^a   Jia, Wei Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Continuous glucose monitoring; diabetes mellitus; hyperandrogenemia; insulin resistance; polycystic ovary syndrome

Indexed keywords

GLUCOSE; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BLOOD GLUCOSE MONITORING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPERANDROGENISM; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; WAIST HIP RATIO;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; COMORBIDITY; DEHYDROEPIANDROSTERONE SULFATE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 84872845312     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12031     Document Type: Article

References (46)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al,. A survey ofthe polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999; 84 (11): 4006-11.
2. Asunciõn M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF,. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000; 85 (7): 2434-8.
3. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS,. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91 (4): 1357-63.
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19 (1): 41-7.
5. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A,. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab. 2007; 92 (12): 4609-14.
6. Barber TM, Wass JA, McCarthy MI, Franks S,. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007; 66 (4): 513-7.
7. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Poromaa IS,. Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome-a long term follow-up. Hum Reprod. 2011; 26 (6): 1462-8.
8. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Sundstrom-Poromaa I,. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertil Steril. 2011; 96 (5): 1271-4.
9. Legro RS, Castracane VD, Kauffman RP,. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004; 59 (2): 141-54.
10. Sharma ST, Nestler JE,. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers. Best Pract Res Clin Endocrinol Metab. 2006; 20 (2): 245-60.
11. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F,. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositol glycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998; 83 (6): 2001-5.
12. Tsilchorozidou T, Overton C, Conway GS,. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004; 60 (1): 1-17.
13. Cascella T, Palomba S, Di Sio I, Manguso F, Giallauria F, De Simone B, et al,. Visceral fat is associatedwith cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod. 2008; 23 (1): 153-9.
14. TürkçüoǦlu I, Kafkasli A, Meydanli MM, Ozyalin F, Taşkapan C,. Independent predictors of cardiovascular risk in polycystic ovarian syndrome. Gynecol Endocrinol. 2011; 27 (11): 915-9.
15. Macut D, Simic T, Lissounov A, Pljesa-Ercegovac M, Bozic I, Djukic T, et al,. Insulin resistance in non-obese women with polycystic ovary syndrome: relation to byproducts of oxidative stress. Exp Clin Endocrinol Diabetes. 2011; 119 (7): 451-5.
16. Huang J, Ni R, Chen X, Huang L, Mo Y, Yang D,. Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China. Reprod Biol Endocrinol. 2010; 8: 142.
17. García-Romero G, Escobar-Morreale HF,. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. Curr Diabetes Rev. 2006; 2 (1): 39-49.
18. Alamzadeh R, Kichler J, Calhoun M,. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol. 2010; 162 (6): 1093-9.
19. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008; 31 (Suppl 1): S55-60.
20. Klonoff DC,. A review of continuous glucose monitoring technology. Diabetes Technol Ther. 2005; 7 (5): 770-5.
21. Klonoff DC,. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 2005; 28 (5): 1231-9.
22. Hirsch IB, Armstrong D, Bergenstal RM, Buckingham B, Childs BP, Clarke WL, et al,. Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). Diabetes Technol Ther. 2008; 10 (4): 232-44; quiz 245-6.
23. Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, et al,. Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care. 2009; 32 (7): 1188-93.
24. Mazze RS, Strock E, Wesley D, Borgman S, Morgan B, Bergenstal R, et al,. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther. 2008; 10 (3): 149-59.
25. Castaldo E, Sabato D, Lauro D, Sesti G, Marini MA,. Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance. PLoS One. 2011; 6 (12): e28312.
26. Hill NR, Oliver NS, Choudary P, Levy JC, Hindmarsh P, Matthews DR,. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011; 13 (9): 921-8.
27. Tao M, Zhou J, Zhu J, Lu W, Jia W,. Continuous glucose monitoring reveals abnormal features of postprandial glycemic excursions in women with polycystic ovarian syndrome. Postgrad Med. 2011; 123 (2): 185-90.
28. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF,. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970; 19 (9): 644-55.
29. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA,. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006; 154 (1): 141-5.
30. Huang A, Brennan K, Azziz R,. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril. 2010; 93 (6): 1938-41.
31. Mehrabian F, Khani B, Kelishadi R, Kermani N,. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci. 2011; 16 (6): 763-9.
32. Stovall DW, Bailey AP, Pastore LM,. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt). 2011; 20 (1): 37-43.
33. Pelusi B, Gambineri A, Pasquali R,. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004; 56 (1): 41-51.
34. Teede H, Hutchison SK, Zoungas S,. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab. 2007; 18 (7): 273-9.
35. Talbott EO, Zborowski J, Rager J, Stragand JR,. Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women Vasc Health Risk Manag. 2008; 4 (2): 453-62.
36. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ,. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care. 2004; 27 (4): 861-8.
37. Singh B, Panda S, Nanda R, Pati S, Mangaraj M, Sahu PK, et al,. Effect of metformin on hormonal and biochemical profile in PCOS before and after therapy. Indian J Clin Biochem. 2010; 25 (4): 367-70.
38. Georgopoulos NA, Saltamavros AD, Vervita V, Karkoulias K, Adonakis G, Decavalas G, et al,. Basal metabolic rate is decreased in women with polycystic ovary syndrome and biochemical hyperandrogenemia and is associated with insulin resistance. Fertil Steril. 2009; 92 (1): 250-5.
39. Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX,. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG. 2009; 116 (12): 1633-9.
40. Zhao X, Zhong J, Mo Y, Chen X, Chen Y, Yang D,. Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2010; 108 (2): 148-51.
41. Yilmaz M, Isaoglu U, Delibas IB, Kadanali S,. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res. 2011; 37 (8): 1020-6.
42. Yildiz BO, Gedik O,. Insulin resistance in polycystic ovary syndrome: hyperandrogenemia versus normoandrogenemia. Eur J Obstet Gynecol Reprod Biol. 2001; 100 (1): 62-6.
43. Dmitrovic R, Katcher HI, Kunselman AR, Legro RS,. Continuous glucose monitoring during pregnancy in women with polycystic ovary syndrome. Obstet Gynecol. 2011; 118 (4): 878-85.
44. Monnier L, Colette C, Dunseath GJ, Owens DR,. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007; 30 (2): 263-9.
45. Lin CH, Huang CH, Tsai JS, Hsieh SH, Sun JH, Huang BY, et al,. Effects of a novel short-term continuous subcutaneous insulin infusion program evaluated by continuous glucose monitoring on young adult type 1 diabetic patients in Taiwan. Endocr J. 2011; 58 (10): 835-40.
46. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, et al,. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011; 10: 19.